We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > immuno-modulating

News List

AMAL Therapeutics Finalises €29 Million (CHF 33.2 Million) Series B Round b3cnewswire
November 12, 2018
The Company will use the funds to progress its lead vaccine (ATP128) toward clinical development and proof-of-concept in colorectal cancer, a leading cause of mortality and a significant market opportunity (€9.6 billion by 2025). The clinical trial is exp
AMAL Therapeutics Finalises €29 Million (CHF 33.2 Million) Series B Round b3cnewswire
November 12, 2018
The Company will use the funds to progress its lead vaccine (ATP128) toward clinical development and proof-of-concept in colorectal cancer, a leading cause of mortality and a significant market opportunity (€9.6 billion by 2025). The clinical trial is exp